A mass balance approach for calculation of recovery and binding enables the use of ultrafiltration as a rapid method for measurement of plasma protein binding for even highly lipophilic compounds

Journal of Pharmaceutical and Biomedical Analysis

Volumn 75, Issue , 2013, Pages 112-117

  Wang, Changguang ^a   Williams, Noelle S ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Mass balance; Non specific binding; Plasma protein binding; Rapid equilibrium dialysis; Ultrafiltration

Indexed keywords

ATENOLOL; HYDROCORTISONE; INDOMETACIN; MEVINOLIN; PACLITAXEL; PARACETAMOL; PROPRANOLOL; SULFADIAZINE; SULFADIMETHOXINE; SULFAMERAZINE; SULFAMETHIZOLE; SULFAMETHOXAZOLE; SULFATHIAZOLE; TERBUTALINE; TOLBUTAMIDE; VERAPAMIL; VINBLASTINE; VISMODEGIB; VORINOSTAT; WARFARIN;

ARTICLE; BINDING KINETICS; BIOLOGICAL MONITORING; DRUG STRUCTURE; EQUILIBRIUM DIALYSIS; LIPOPHILICITY; LIQUID CHROMATOGRAPHY; MOLECULAR WEIGHT; PH; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; ULTRAFILTRATION;

ALGORITHMS; ANIMALS; BINDING SITES; BLOOD PROTEINS; DIALYSIS; DRUG EVALUATION, PRECLINICAL; DRUG STABILITY; DRUGS, INVESTIGATIONAL; HUMANS; HYDROGEN-ION CONCENTRATION; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; KINETICS; MICE; PHYSICOCHEMICAL PHENOMENA; PROTEIN BINDING; ULTRAFILTRATION;

EID: 84871735543     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2012.11.018     Document Type: Article

References (23)

1. Urien S., Tillement J.P., Barre J. The significance of plasma-protein binding in drug research. Pharmacokinetic Optimization in Drug Research 2001, 189-197. Verlag Helvetica Chimica Acta, Zurich, Switzerland. B. Testa, H.V. Waterbeemd, G. Folkers, R. Guy (Eds.).
2. Barre J., Chamouard J.M., Houin G., Tillement J.P. Equilibrium dialysis, ultrafiltration, and ultracentrifugation compared for determining the plasma-protein-binding characteristics of valproic acid. Clin. Chem. 1985, 31:60-64.
3. Waters N.J., Jones R., Williams G., Sohal B. Validation of a rapid equilibrium dialysis approach for the measurement of plasma protein binding. J. Pharm. Sci. 2008, 97:4586-4595.
4. Tsai T.H. Assaying protein unbound drugs using microdialysis techniques. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 2003, 797:161-173.
5. Deng Y., Wong H., Graham R.A., Liu W., Shen H.S., Shi Y., Wang L., Meng M., Malhi V., Ding X., Dean B. Determination of unbound vismodegib (GDC-0449) concentration in human plasma using rapid equilibrium dialysis followed by solid phase extraction and high-performance liquid chromatography coupled to mass spectrometry. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 2011, 879:2119-2126.
6. Tasker R.A., Nakatsu K. Factors affecting ultrafiltration-assessed values for drug binding. Clin. Chem. 1982, 28:1244-1246.
7. Zhirkov Y., Piotrovskii V.K. On the usefulness of ultrafiltration in drug-protein binding studies. J. Pharm. Pharmacol. 1984, 36:844-845.
8. Lee K.J., Mower R., Hollenbeck T., Castelo J., Johnson N., Gordon P., Sinko P.J., Holme K., Lee Y.H. Modulation of nonspecific binding in ultrafiltration protein binding studies. Pharm. Res. 2003, 20:1015-1021.
9. Taylor S., Harker A. Modification of the ultrafiltration technique to overcome solubility and non-specific binding challenges associated with the measurement of plasma protein binding of corticosteroids. J. Pharm. Biomed. Anal. 2006, 41:299-303.
10. Brash J.L., Lyman D.J. Adsorption of plasma proteins in solution to uncharged hydrophobic polymer surfaces. J. Biomed. Mater. Res. 1969, 3:175-189.
11. Thakurta S.G., Subramanian A. Evaluation of in situ albumin binding surfaces: as study of protein adsorption and platelet adhesion. J. Mater. Sci. Mater. Med. 2011, 22:137-149.
12. Macmillan K.S., Naidoo J., Liang J., Melito L., Williams N.S., Morlock L., Huntington P.J., Estill S.J., Longgood J., Becker G.L., McKnight S.L., Pieper A.A., De Brabander J.K., Ready J.M. Development of proneurogenic, neuroprotective small molecules. J. Am. Chem. Soc. 2011, 133:1428-1437.
13. Rasko D.A., Moreira C.G., Li D.R., Reading N.C., Ritchie J.M., Waldor M.K., Williams N., Taussig R., Wei S., Roth M., Hughes D.T., Huntley J.F., Fina M.W., Falck J.R., Sperandio V. Targeting QseC signaling and virulence for antibiotic development. Science 2008, 32:1078-1080.
14. Lu J., Ma Z., Hsieh J.C., Fan C.W., Chen B., Longgood J.C., Williams N.S., Amatruda J.F., Lum L., Chen C. Structure-activity relationship studies of small-molecule inhibitors of Wnt response. Bioorg. Med. Chem. Lett. 2009, 19:3825-3827.
15. Mata M.A., Satterly N., Versteeg G.A., Frantz D., Wei S., Williams N., Schmolke M., Pena-Llopis S., Brugarolas J., Forst C., White M.A., Garcia-Sastre A., Roth M.G., Fontoura B.M.A. Chemical inhibition of RNA viruses reveals REDD1 as host defense factor. Nat. Chem. Biol. 2011, 7:712-719.
16. Li L., Thomas R.M., Suzuki H., De Brabander J.K., Wang X., Harran P.G. A small molecule Smac mimic potentiates TRAIL- and TNFalpha-mediated cell death. Science 2004, 305:1471-1474.
17. Williams N.S., Burgett A.W.G., Atkins A.S., Wang X., Harran P.G., McKnight S.L. Therapeutic anti-cancer efficacy of a synthetic diazonamide analog in the absence of overt toxicity. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:2074-2079.
18. Dow N., Determination of compound binding to plasma proteins Current Protocols in Pharmacology 2006, John Wiley & Sons Inc., Hoboken, NJ, 7.5.1-7.5.15. G. Taylor (Ed.).
19. Kochansky C.J., McMasters D.R., Lu P., Koeplinger K.A., Kerr H.H., Shou M., Korzekwa K.R. Impact of pH on plasma protein binding in equilibrium dialysis. Mol. Pharm. 2008, 5:438-448.
20. Milligan T.P., Morris H.C., Hammond P.M., Price C.P. Studies on paracetamol binding to serum proteins. Ann. Clin. Biochem. 1994, 31:492-496.
21. Zhang F.L., Xue J.P., Shao J.W., Lee J. Plasma protein binding data and guidance for study design of 222 drugs. Drug Discov. Today 2011, 17:475-485.
22. Reynolds Martindale J.E.F. The Extra Pharmacopeia 1989, The Pharmaceutical Press, London. 29th ed.
23. Obach R.S., Lombardo F., Waters N.J. Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug Metab. Disp. 2008, 36:1385-1405.